07:00 Mon 14 Sep 2020
Shield Therapeutics - Notice of Results

("Shield" or the "Group" or the "Company")
Notice of Results
Analyst and Investor Briefings
Analyst briefing
A briefing open to analysts will take place remotely via video conference call on Wednesday
Investor briefing
The presentation will be hosted through the digital platform
https://www.investormeetcompany.com/shield-therapeutics-plc/register-investor
For those investors who have already registered and added to meet the Company, they will automatically be invited.
Questions can be submitted pre-event via your
For further information please contact:
| |
| +44 (0)20 7186 8500 |
|
|
Nominated Adviser and Joint Broker |
|
|
|
| +44 (0)20 7418 8900 |
Joint Broker finnCap Ltd |
+44 (0)20 7220 0500 |
|
|
Financial PR & IR Advisor |
|
Walbrook PR | +44 (0)20 7933 8780 or shield@walbrookpr.com |
Paul McManus/Lianne Cawthorne | +44 (0)7980 541 893 / +44 (0)7584 391 303 |
About
Shield is a de-risked, specialty pharmaceutical company focused on commercialising its lead product, Feraccru®/Accrufer®, a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Feraccru®/Accrufer® has been approved for use in the United States,
For more information, please visit www.shieldtherapeutics.com. Follow Shield on Twitter @ShieldTx
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
FOR OUR FULL DISCLAIMER CLICK HEREDeep dive
